Hammarskiöld & Co advised Medical Prognosis Institute A/S in connection with the cross-border merger between Medical Prognosis Institute and Oncology Venture Sweden AB (publ)

Hammarskiöld & Co advised Medical Prognosis Institute A/S in connection with the cross-border merger between Medical Prognosis Institute and Oncology Venture Sweden AB (publ).

Medical Prognosis Institute is a Danish company specialised in improving cancer patients’ lives by developing personalised medicine using its Drug Response Predictor (DRP®) technology. Medical Prognosis Institute’s shares are listed on Nasdaq First North, Stockholm.

Prior to the merger, Oncology Venture was a Swedish company engaged in the research and development of anti-cancer drugs via the wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture’s shares were previously listed on Spotlight Stock Market (formerly AktieTorget).

Combining these two highly complementary businesses is intended to result in a leading integrated oncology biotechnology company with a promising anticancer drug pipeline resting on a proprietary patient screening technology to predict drug response. The merger is implemented with Medical Prognosis Institute as the transferee company and Oncology Venture as the transferor company. In connection with the implementation of the merger, Medical Prognosis Institute has changed its name to “Oncology Venture A/S”. The company’s shares will continue to be listed on Nasdaq First North, Stockholm.

Hammarskiöld & Co’s team consisted of Jakob Falkman (Partner), Carl-Johan Pousette (Partner), Erik Löfwall (Partner), Nina Sna Ahmad (), Marcus Tipner (Associate).